New combo therapy aims to shrink advanced lung tumors
NCT ID NCT07414953
First seen Feb 19, 2026 · Last updated Apr 29, 2026 · Updated 10 times
Summary
This early-stage study tests a new drug called HS-10504 combined with other treatments in about 400 adults with advanced non-small cell lung cancer that has worsened after prior therapy. The goal is to find the safest and most effective dose and to see if the combination can shrink tumors. Participants must have a specific gene mutation (EGFR or MET) and be in fairly good health.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.